<DOC>
	<DOCNO>NCT00277251</DOCNO>
	<brief_summary>This trial test hypothesis among 20 child adolescents Children 's Hospital , Boston Crohn ’ disease , ulcerative colitis , systemic-onset juvenile rheumatoid arthritis , juvenile dermatomyositis , systemic lupus erythematosus , mixed connective tissue disease vasculitis , treatment glucocorticoid-associated osteopenia osteoporosis 18 month alendronate ( FOSAMAX® , Merck &amp; Co. , Inc. ) result great improvement mean change individual AP spine bone mineral density ( BMD ) ( gm/cm2 ) determine dual energy X-ray absorptiometry ( DXA ) treatment 18 month standard care therapy .</brief_summary>
	<brief_title>Alendronate Osteoporosis Study</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Subjects must diagnose either ulcerative colitis , Crohn ’ disease , systemiconset juvenile rheumatoid arthritis , juvenile dermatomyositis , systemic lupus erythematosus ( SLE ) , mixed connective tissue disease ( MCTD ) vasculitis accord standard criterion available , accord treat physician available . Subjects must diminish AP lumbar spine ( L1L4 ) BMD DXA ( Hologic 4500 ) Z score ≤ –1.5 SD assess within 8 week Baseline Visit . Subjects must receive daily , alternate day weekly systemic glucocorticoid therapy minimum six month total lifetime . Subjects must age 8 21 year , 11 month , randomization . Although subject young 8 year age may affect osteoporosis , limited normative data prevents assignment BMD Z score group . Regarding subject childbearing potential Females least one menstrual cycle must either abstinent must use effective method birth control . Current recent ( within 6 month ) treatment therapeutic dos bisphosphonate , calcitonin , human growth hormone , heparin , agent know alter bone density A history recent ( within one year screening ) major upper gastrointestinal ( GI ) disease ( jejunum ) , include , limited , peptic ulcer , esophageal disease active GI bleeding , ever surgery upper GI tract pyloroplasty . A history abnormality esophagus delay esophageal emptying , stricture achalasia Hyperthyroidism ( suppress thyroid stimulate hormone ( TSH ) elevate free thyroxine ( T4 ) ) , hyperparathyroidism ( elevate parathyroid hormone ( PTH ) ) , malignancy , rickets , osteomalacia ( history ) , assess within 8 week Baseline Visit . 25 ( OH ) vitamin D 20 mg/L Planned current pregnancy and/or breastfeed Renal dysfunction define dependence dialysis creatinine clearance &lt; 35 ml/min , assess within 4 week Baseline Visit . Creatinine clearance = [ ( height cm x 0.55 ) /plasma creatinine ] female male &lt; 13 year old ; [ ( height cm x 0.70 ) /plasma creatinine ] males ³ 13 year old . Hepatic insufficiency define SGPT SGOT great twice normal age , assess within 4 week Baseline Visit . Uncorrected hypocalcemia ( ionized calcium &gt; 10 % ageadjusted range ) , assess within 4 week Baseline Visit Known suspect hypersensitivity bisphosphonates Inability follow instruction dose , include unable swallow study medication plain water first thing morning , stand sit upright without food beverage least 30 minute follow dose next meal Weight great 136 kg ( 300 lb ) , DXA reliable subject size Weight le 17 kg ( 37 lb ) , assess within 8 week Baseline Visit Permanent foreign body ( prosthetic , surgical clip , permanent earring/umbilical ring ) region result study Enrollment Procedures interest , soft tissue calcinosis overlie region interest Inability undergo dual energy Xray absorptiometry CT scan Developmental cognitive delay may interfere cooperation and/or compliance procedure Subject expect move area study period , render followup per protocol impractical</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>Crohn ’ disease</keyword>
	<keyword>systemic-onset juvenile rheumatoid arthritis</keyword>
	<keyword>juvenile dermatomyositis</keyword>
	<keyword>systemic lupus erythematosus ( SLE )</keyword>
	<keyword>Mixed connective tissue disease ( MCTD )</keyword>
	<keyword>vasculitis</keyword>
</DOC>